Buy Ibrance (Palbociclib)
Price range: €1,275.00 through €1,599.00
Select options
This product has multiple variants. The options may be chosen on the product page
What is Ibrance (palbociclib) for?
Palbociclib is indicated for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. It is indicated in combination with an aromatase inhibitor (hormone therapy) as initial endocrine-based therapy in postmenopausal women or with fulvestrant in women with disease progression after endocrine therapy.How does Ibrance (palbociclib) work?
Palbociclib is an inhibitor of cyclin-dependent kinase (CDK) 4 and 6.
Before a cell can divide, it must go through four phases. The first phase is a growth phase (G1 phase), the second a synthesis phase (S phase), the third another growth phase (G2 phase), and the final phase, in which the cell divides (M phase). Cancer cells divide extremely rapidly and pass through these four phases quickly. Palbociclib blocks the transition from the first G1 phase to the second S phase. This occurs by inhibiting cyclin-dependent kinases 4 and 6 (CDK4 and CDK6) – two proteins involved in entering the S phase [1] .